 Flavia Hoyte
Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 30 | 2025 | 1795 | 3.750 |
Why?
| | Anti-Asthmatic Agents | 18 | 2025 | 260 | 3.370 |
Why?
| | Biological Products | 11 | 2025 | 258 | 2.750 |
Why?
| | Rhinitis, Allergic | 4 | 2024 | 42 | 1.190 |
Why?
| | Sinusitis | 4 | 2024 | 227 | 1.150 |
Why?
| | Nasal Polyps | 3 | 2024 | 59 | 1.150 |
Why?
| | Hypersensitivity | 3 | 2024 | 254 | 1.080 |
Why?
| | Rhinitis | 3 | 2024 | 169 | 1.050 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2025 | 994 | 0.900 |
Why?
| | Remission Induction | 2 | 2025 | 309 | 0.850 |
Why?
| | Adrenal Cortex Hormones | 9 | 2025 | 482 | 0.850 |
Why?
| | Bronchodilator Agents | 3 | 2023 | 187 | 0.770 |
Why?
| | Curcumin | 1 | 2022 | 27 | 0.730 |
Why?
| | Urticaria | 1 | 2022 | 38 | 0.720 |
Why?
| | Pancreatitis | 2 | 2012 | 146 | 0.670 |
Why?
| | Respiratory Tract Diseases | 2 | 2012 | 176 | 0.640 |
Why?
| | Desensitization, Immunologic | 2 | 2018 | 89 | 0.640 |
Why?
| | Allergens | 2 | 2024 | 390 | 0.610 |
Why?
| | Aspirin | 3 | 2018 | 407 | 0.600 |
Why?
| | Sublingual Immunotherapy | 1 | 2018 | 4 | 0.570 |
Why?
| | Exhalation | 1 | 2018 | 29 | 0.560 |
Why?
| | Severity of Illness Index | 8 | 2025 | 2945 | 0.460 |
Why?
| | Nebulizers and Vaporizers | 3 | 2025 | 62 | 0.460 |
Why?
| | Immunoglobulin E | 4 | 2025 | 315 | 0.460 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 2 | 2025 | 26 | 0.440 |
Why?
| | Nitric Oxide | 2 | 2024 | 894 | 0.430 |
Why?
| | Anti-Allergic Agents | 1 | 2014 | 40 | 0.410 |
Why?
| | Histamine | 3 | 2022 | 53 | 0.400 |
Why?
| | Skin Tests | 2 | 2024 | 94 | 0.390 |
Why?
| | Voice Disorders | 1 | 2012 | 23 | 0.380 |
Why?
| | Vocal Cords | 1 | 2012 | 27 | 0.380 |
Why?
| | Eosinophils | 6 | 2025 | 316 | 0.370 |
Why?
| | Administration, Inhalation | 5 | 2025 | 571 | 0.360 |
Why?
| | Double-Blind Method | 4 | 2024 | 2060 | 0.350 |
Why?
| | Muscarinic Antagonists | 2 | 2025 | 30 | 0.350 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2011 | 20 | 0.340 |
Why?
| | Histamine Antagonists | 1 | 2011 | 21 | 0.340 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2011 | 25 | 0.340 |
Why?
| | Humans | 39 | 2025 | 145491 | 0.340 |
Why?
| | Pulmonary Eosinophilia | 2 | 2022 | 27 | 0.320 |
Why?
| | Quality of Life | 7 | 2025 | 3195 | 0.270 |
Why?
| | Formoterol Fumarate | 2 | 2025 | 6 | 0.270 |
Why?
| | Treatment Outcome | 8 | 2025 | 11831 | 0.260 |
Why?
| | Cost of Illness | 2 | 2024 | 324 | 0.260 |
Why?
| | Practice Guidelines as Topic | 3 | 2024 | 1585 | 0.250 |
Why?
| | Albuterol | 2 | 2023 | 76 | 0.230 |
Why?
| | Chronic Disease | 4 | 2024 | 1816 | 0.230 |
Why?
| | Skin | 2 | 2022 | 766 | 0.220 |
Why?
| | Allergy and Immunology | 1 | 2024 | 43 | 0.200 |
Why?
| | Biomarkers | 4 | 2025 | 4283 | 0.200 |
Why?
| | Geography | 1 | 2024 | 204 | 0.200 |
Why?
| | Patient Preference | 1 | 2025 | 226 | 0.190 |
Why?
| | Drug Therapy, Combination | 3 | 2025 | 1046 | 0.190 |
Why?
| | Budesonide | 2 | 2023 | 49 | 0.180 |
Why?
| | Adrenergic beta-Agonists | 2 | 2025 | 93 | 0.170 |
Why?
| | Bayes Theorem | 1 | 2022 | 426 | 0.160 |
Why?
| | Adult | 13 | 2025 | 40707 | 0.160 |
Why?
| | Cross-Over Studies | 1 | 2022 | 607 | 0.160 |
Why?
| | Aged | 8 | 2025 | 26125 | 0.150 |
Why?
| | Male | 13 | 2025 | 72817 | 0.150 |
Why?
| | Female | 14 | 2025 | 78763 | 0.140 |
Why?
| | Registries | 5 | 2025 | 2410 | 0.140 |
Why?
| | Middle Aged | 9 | 2025 | 36176 | 0.140 |
Why?
| | Child | 7 | 2025 | 22680 | 0.130 |
Why?
| | Biofeedback, Psychology | 1 | 2018 | 35 | 0.130 |
Why?
| | Mastocytosis, Systemic | 1 | 2017 | 7 | 0.130 |
Why?
| | Dystonia | 1 | 2017 | 28 | 0.130 |
Why?
| | Movement Disorders | 1 | 2017 | 70 | 0.120 |
Why?
| | Caregivers | 1 | 2025 | 1070 | 0.120 |
Why?
| | Omalizumab | 1 | 2016 | 43 | 0.120 |
Why?
| | Administration, Oral | 2 | 2025 | 863 | 0.120 |
Why?
| | Mast Cells | 1 | 2017 | 148 | 0.120 |
Why?
| | Aged, 80 and over | 2 | 2024 | 8326 | 0.110 |
Why?
| | Young Adult | 4 | 2024 | 14192 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 478 | 0.100 |
Why?
| | Leukocyte Count | 2 | 2025 | 316 | 0.100 |
Why?
| | Heart Rate | 1 | 2018 | 859 | 0.100 |
Why?
| | Adolescent | 5 | 2024 | 22485 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1269 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 2185 | 0.090 |
Why?
| | Comorbidity | 3 | 2024 | 1659 | 0.090 |
Why?
| | Disease Management | 1 | 2016 | 654 | 0.090 |
Why?
| | Receptors, Histamine | 1 | 2011 | 2 | 0.090 |
Why?
| | History, 19th Century | 1 | 2011 | 63 | 0.090 |
Why?
| | Administration, Intranasal | 1 | 2011 | 94 | 0.080 |
Why?
| | Pregnancy | 2 | 2016 | 7197 | 0.080 |
Why?
| | History, 20th Century | 1 | 2011 | 327 | 0.080 |
Why?
| | Medication Adherence | 1 | 2014 | 543 | 0.080 |
Why?
| | Cohort Studies | 3 | 2025 | 5992 | 0.070 |
Why?
| | Drug Combinations | 2 | 2023 | 397 | 0.070 |
Why?
| | United States | 2 | 2024 | 16115 | 0.070 |
Why?
| | Age Factors | 1 | 2016 | 3340 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1507 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1755 | 0.070 |
Why?
| | Algorithms | 1 | 2014 | 1855 | 0.060 |
Why?
| | Disease Progression | 2 | 2022 | 2862 | 0.050 |
Why?
| | Ethanolamines | 1 | 2023 | 14 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2025 | 517 | 0.050 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2023 | 50 | 0.050 |
Why?
| | Multimorbidity | 1 | 2023 | 64 | 0.050 |
Why?
| | Steroids | 1 | 2023 | 160 | 0.050 |
Why?
| | Age of Onset | 1 | 2024 | 554 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 116 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2025 | 1332 | 0.040 |
Why?
| | Precision Medicine | 1 | 2025 | 456 | 0.040 |
Why?
| | Seasons | 1 | 2023 | 559 | 0.040 |
Why?
| | Prospective Studies | 2 | 2023 | 8039 | 0.040 |
Why?
| | Animals | 1 | 2022 | 38141 | 0.040 |
Why?
| | Databases, Factual | 1 | 2025 | 1500 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2023 | 842 | 0.030 |
Why?
| | Carbidopa | 1 | 2017 | 11 | 0.030 |
Why?
| | Myoclonus | 1 | 2017 | 17 | 0.030 |
Why?
| | Cell Degranulation | 1 | 2017 | 41 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2950 | 0.030 |
Why?
| | Diphenhydramine | 1 | 2017 | 37 | 0.030 |
Why?
| | Levodopa | 1 | 2017 | 41 | 0.030 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 344 | 0.030 |
Why?
| | Dopamine | 1 | 2017 | 295 | 0.030 |
Why?
| | Scoliosis | 1 | 2017 | 224 | 0.030 |
Why?
| | Electroencephalography | 1 | 2018 | 563 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 871 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2018 | 775 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5891 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2883 | 0.020 |
Why?
|
|
Hoyte's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|